PanGen Biotech Overview

  • Founded
  • 1999

Founded
  • Status
  • Public

  • Employees
  • 85

Employees
  • Stock Symbol
  • 222110

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $4.39

  • (As of Wednesday Closing)

PanGen Biotech General Information

Description

Pangen Biotech Inc is a biotechnology company. It is engaged in development of biosimilar products and technology transfer services for biologics development. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc.

Contact Information

Website
www.pangen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Primary Office
  • 306 Sinwon-ro, Yeongtong-gu
  • 4th Floor, Innoplex 2-dong
  • Suwon-si, Gyeonggi 16675
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PanGen Biotech Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.39 $4.34 $3.81 - $8.20 $46.9M 10.7M 52K -$0.36

PanGen Biotech Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 44,749 79,310 89,442 58,652
Revenue 5,565 6,928 5,244 2,471
EBITDA (2,655) (1,401) (1,720) (5,648)
Net Income (3,895) (2,890) (3,689) (7,665)
Total Assets 14,842 36,367 33,283 33,740
Total Debt 4 15,713 16,865 15,009
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PanGen Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PanGen Biotech‘s full profile, request access.

Request a free trial

PanGen Biotech Patents

PanGen Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11155635-B2 Anti-coagulation factor viii antibody and use thereof Active 14-Dec-2016 000000000 0
US-20200277401-A1 Anti-coagulation factor viii antibody and use thereof Active 14-Dec-2016 000000000
EP-2692867-A4 Expression vector for animal cells Active 30-Mar-2011 000000000
EP-2692867-A2 Expression vector for animal cells Active 30-Mar-2011 000000000
EP-2692867-B1 Expression vector for animal cells Active 30-Mar-2011 C12N15/85
To view PanGen Biotech’s complete patent history, request access »

PanGen Biotech Executive Team (4)

Name Title Board Seat Contact Info
Jaeseung Yoon Ph.D Co-Founder, President & Co-Chief Executive Officer
Youngboo Kim President & Chief Executive Officer
Jae-Hong Jang Chief Financial Officer & Director
Tae-Ho Byun Chief Operating Officer & Vice President
To view PanGen Biotech’s complete executive team members history, request access »

PanGen Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PanGen Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PanGen Biotech‘s full profile, request access.

Request a free trial

PanGen Biotech Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 17-Jul-2020 00000 0000 Drug Discovery 00000000
To view PanGen Biotech’s complete investments history, request access »